Copyright
©The Author(s) 2021.
World J Diabetes. Sep 15, 2021; 12(9): 1386-1400
Published online Sep 15, 2021. doi: 10.4239/wjd.v12.i9.1386
Published online Sep 15, 2021. doi: 10.4239/wjd.v12.i9.1386
Table 1 Structural and pharmacokinetic characteristics of the four anti-vascular endothelial growth factor drugs[55]
| Pegaptanib | Ranibizumab | Bevacizumab | Aflibercept | |
| Structure | Pegylated aptamer | Recombinant monoclonal antibody fragment (Fab) | Recombinant monoclonal antibody (Mab) | Fusion protein |
| Molecular weight (kDa) | 50 | 48 | 149 | 115 |
| Recommended dose (volume) | 0.3 mg (0.9 mL) | 0.5 mg (0.05 mL) | 1.25 mg (0.05 mL) | 2 mg (0.05 mL) |
| Intravitreal half-life (d) | 3.9 (monkeys) | 2.6-2.88 (rabbits) | 4.32-6.61 (rabbits) | 4.5-4.7 (rabbits) |
| 3-3.2 (monkeys) | 3.1 (monkeys) | |||
| 7.1 (humans) | 6.7-10 (humans) | |||
| Serum half-life humans (d) | 10 | 0.25 | 21 | 18 |
- Citation: Choo PP, Md Din N, Azmi N, Bastion MLC. Review of the management of sight-threatening diabetic retinopathy during pregnancy. World J Diabetes 2021; 12(9): 1386-1400
- URL: https://www.wjgnet.com/1948-9358/full/v12/i9/1386.htm
- DOI: https://dx.doi.org/10.4239/wjd.v12.i9.1386